Naomi Lowy

3 weeks ago | mondaq.com | Naomi Lowy |James Valentine

There is much change happening at FDA. In the wake of the April1st reduction in force, there has been a great deal ofuncertainty about what the impacts will be. This rings particularlytrue amongst the rare disease patient community, along with manysmall biotech companies (and their investors) that take on the riskof developing orphan drugs for exceedingly small patientpopulations.